| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
40,247 |
37,091 |
$4.16M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
19,289 |
17,830 |
$1.94M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
8,235 |
7,318 |
$843K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,508 |
1,281 |
$147K |
| S9088 |
Services provided in an urgent care center (list in addition to code for service) |
7,261 |
6,411 |
$74K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
658 |
599 |
$68K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
427 |
420 |
$49K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
5,173 |
4,788 |
$31K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
6,306 |
3,039 |
$12K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
5,604 |
5,284 |
$11K |
| 81003 |
|
3,286 |
2,984 |
$8K |
| 87428 |
|
675 |
637 |
$4K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
77 |
77 |
$4K |
| 81025 |
|
1,231 |
1,134 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
106 |
101 |
$590.93 |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
180 |
178 |
$225.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
13 |
13 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
16 |
14 |
$0.00 |
| 87807 |
|
41 |
40 |
$0.00 |